Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Purpose: Few studies have reported the prevalence of inflammatory bowel disease unclassified (IBDU) among Korean pediatric IBD (PIBD) population. To address this gap, we used two tertiary centers and nationwide population-based healthcare administrative data to estimate the prevalence of Korean pediatric IBDU at the time of diagnosis.

Methods: We identified 136 patients aged 2-17 years with newly diagnosed IBD (94 Crohn's disease [CD] and 42 ulcerative colitis [UC]) from two tertiary centers in Korea between 2005 and 2017. We reclassified these 136 patients using the revised Porto criteria. To estimate the population-based prevalence, we analyzed Korean administrative healthcare data between 2005 and 2016, which revealed 3,650 IBD patients, including 2,538 CD and 1,112 UC. By extrapolating the reclassified results to a population-based dataset, we estimated the prevalence of PIBD subtypes.

Results: Among the 94 CD, the original diagnosis remained unchanged in 93 (98.9%), while the diagnosis of one (1.1%) patient was changed to IBDU. Among the 42 UC, the original diagnosis remained unchanged in 13 (31.0%), while the diagnoses in 11 (26.2%), 17 (40.5%), and one (2.4%) patient changed to atypical UC, IBDU, and CD, respectively. The estimated prevalences of CD, UC, atypical UC, and IBDU in the Korean population were 69.5%, 9.4%, 8.0%, and 13.1%, respectively.

Conclusion: This study is the first in Korea to estimate the prevalence of pediatric IBDU. This prevalence (13.1%) aligns with findings from Western studies. Large-scale prospective multicenter studies on PIBDU are required to examine the clinical features and outcomes of this condition.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11254648PMC
http://dx.doi.org/10.5223/pghn.2024.27.4.206DOI Listing

Publication Analysis

Top Keywords

inflammatory bowel
12
bowel disease
12
korean pediatric
12
prevalence inflammatory
8
disease unclassified
8
revised porto
8
porto criteria
8
ibdu korean
8
tertiary centers
8
estimate prevalence
8

Similar Publications

Combining two advanced therapies may improve outcomes in Crohn's disease (CD) refractory to monotherapy. We conducted a descriptive case series of 27 patients with CD who initiated combination therapy with upadacitinib and infliximab (n = 1), risankizumab (n = 17), ustekinumab (n = 3) or vedolizumab (n = 6). At 12 weeks, 24 achieved clinical response and 9 achieved steroid-free remission.

View Article and Find Full Text PDF

Evaluating a novel intestinal tampon for adults with ileostomy: pilot study.

Br J Nurs

September 2025

Professor, Department of Digestive Diseases, Transplantation and General Surgery, Copenhagen University Hospital Rigshospitalet/Department of Clinical Medicine, University of Copenhagen, Denmark.

Introduction: Approximately 1 million people live with ileostomies and rely on stoma bags in their daily lives. They do not have access to alternative products. To address alternatives, InterPoc™, an absorbent intestinal tampon, has been developed.

View Article and Find Full Text PDF

Introduction: Targeted infection imaging is crucial for accurate diagnosis in postpartum women. This project uses 99mTc-labeled cefixime to develop a radiopharmaceutical for detecting, distinguishing, and treating infections and abscesses in women.

Method: Technetium (TcO4-) chelated with cefixime, reduced by stannous chloride, confirmed via thin-layer chromatography.

View Article and Find Full Text PDF

Drug Delivery Strategies for the Lower GI Tract: A Review.

Adv Healthc Mater

September 2025

Smart Polymeric Biomaterials Research Group, Campus Group T, KU Leuven, Andreas Vesaliusstraat 13, Leuven, 3000, Belgium.

The lower gastrointestinal (GI) tract is affected by a range of diseases, including colorectal cancer and inflammatory bowel disease, among others. Effective treatment of these conditions requires drug delivery systems (DDSs) capable of precise targeting. While pH- and enzyme-sensitive DDSs are the most used, they often suffer from premature drug release and target specificity, limiting their efficacy.

View Article and Find Full Text PDF

Introduction: The effect of inflammatory bowel disease (IBD) on adverse in-hospital outcomes after radical prostatectomy (RP) for nonmetastatic prostate cancer (PCa) is not well known.

Materials And Methods: Descriptive analyses, propensity score matching and multivariable logistic regression models were used within the National Inpatient Sample (2000-2019) RP patients, after stratification according to Crohn's disease (CD) vs. ulcerative colitis (UC) vs.

View Article and Find Full Text PDF